Pyridoxamine — Advanced Glycation (AGE) Cross-Link Inhibition

#1

I wanted to dig a little deeper into the history and clinical studies on Pyridoxamine (pyridoxamine dihydrochloride ), as its own topic, as it seems interesting from the perspective of providing benefits in slowed vasculature matrix stiffening and preserved microvascular compliance.

Starting from this post: The Stiffening Trap: How Aging Tissues Strangle Their Own Blood Supply - #2 by RapAdmin

Pyridoxamine Background

Definition and Biochemical Mechanism

Pyridoxamine is one of the three natural, unphosphorylated B6 vitamers, alongside pyridoxine and pyridoxal. In vivo, it is phosphorylated by pyridoxal kinase and processed through the vitamin B6 metabolic pathway to form the active coenzyme pyridoxal 5’-phosphate (PLP) (Albersen et al., 2013).

Beyond its foundational role as a vitamin precursor, pyridoxamine acts as a powerful inhibitor of advanced glycation end-products (AGEs) and advanced lipoxidation end-products (ALEs) (Chetyrkin et al., 2007). It suppresses these pathogenic pathways via a distinct multi-pronged mechanism:

  • Dicarbonyl Scavenging: It directly traps and detoxifies highly reactive carbonyl species (RCS) and dicarbonyl intermediates, such as methylglyoxal (MGO), glyoxal, and 3-deoxyglucosone (3-DG) (Chetyrkin et al., 2007).
  • Matrix Protection: By quenching these intermediates, pyridoxamine prevents them from modifying critical arginine and lysine residues on long-lived extracellular matrix proteins, such as collagen IV, thereby preserving structural cellular-matrix interactions (Chetyrkin et al., 2007).
  • Metal Chelation and ROS Suppression: It chelates catalytic transition metals involved in glycoxidation reactions, reducing the downstream generation of reactive oxygen species (ROS) (Telen, 2020).

Commercialization History and Regulatory Status

The commercial history of pyridoxamine dihydrochloride (the salt formulation typically leveraged in clinical development) is defined by a significant transition from a retail nutritional supplement to a stalled pharmaceutical asset:

  • The Dietary Supplement Exclusion (2009): Prior to 2009, pyridoxamine was commercially available over-the-counter in the United States within various dietary supplement formulations. However, a biopharmaceutical company, BioStratum Inc., submitted an Investigational New Drug (IND) application for pyridoxamine to develop it as a therapeutic agent. Because the IND was filed before extensive marketing of the ingredient as a supplement took place, the US Food and Drug Administration (FDA) issued a final administrative ruling in January 2009. Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, the FDA officially excluded pyridoxamine from the definition of a dietary supplement, removing it from the commercial retail market.
  • NephroGenex and Phase 3 Pitfalls: The clinical development rights for the molecule (designated as Pyridorin) were subsequently held by NephroGenex Inc. The company successfully executed Phase 2 clinical trials targeting diabetic nephropathy and initiated a Phase 3 registration trial protocol known as the PIONEER study (NCT02156843). However, due to the extreme capital expenditures required to sustain a global, multi-center Phase 3 renal trial, NephroGenex experienced severe financial distress and filed for Chapter 11 bankruptcy in 2016.
  • Current Status: Pyridoxamine dihydrochloride remains classified by the FDA as an investigational drug substance. Because no pharmaceutical entity has successfully completed Phase 3 development to secure a New Drug Application (NDA) approval, the compound occupies a regulatory limbo: it is legally banned from inclusion in over-the-counter dietary supplements in the US, yet unavailable as a commercial prescription medicine.

Prospective Human Benefits and Clinical Evidence

1. Renoprotection in Chronic and Acute Kidney Disease

In a large-scale, 52-week, randomized, double-blind, placebo-controlled trial involving 317 patients with proteinuric type 2 diabetic nephropathy, Pyridorin (administered at 150 mg or 300 mg twice daily) failed to demonstrate a statistically significant change in total serum creatinine compared to placebo across the entire unselected cohort (Lewis et al., 2012). However, a profound treatment effect was revealed during baseline tertile sub-group analysis: patients entering the study with the least severe renal impairment (the lowest tertile of baseline serum creatinine) exhibited a statistically significant preservation of estimated glomerular filtration rate (eGFR) and a significantly slower rate of serum creatinine elevation (Lewis et al., 2012).

Additionally, translational models demonstrate that pyridoxamine mitigates ischemia-reperfusion acute kidney injury (AKI), significantly decreasing acute tubular damage, preserving functional organ recovery, and halting long-term post-injury interstitial fibrosis (Skrypnyk et al., 2016).

2. Mitigation of Vascular Aging and Arterial Stiffness

Vascular aging is structurally characterized by the cross-linking of arterial collagen by AGEs, driving large artery stiffness and isolated systolic hypertension. Chronic pyridoxamine administration in aging models prevents large artery stiffening, attenuates systolic blood pressure elevation, and fully preserves cerebral artery endothelium-dependent dilation by restoring nitric oxide (NO) bioavailability (Reeve et al., 2022).

3. Protection Against Cardiomyopathy

Pyridoxamine has demonstrated a clear capacity to shield cardiac tissue against drug-induced toxicities, such as doxorubicin-induced dilated cardiomyopathy. It functions by minimizing myocardial fibrosis, lowering systemic inflammatory cytokine expression, and restoring intracellular iron and redox regulation at the genomic level (Haesen et al., 2024).

4. Additional Microvascular and Carbonyl-Stress Pathologies

  • Sickle Cell Disease (SCD): Pyridoxamine acts on peripheral tissues to limit neutrophil degranulation and platelet aggregation, presenting an active therapeutic target to minimize vaso-occlusive crises and hemolytic tissue injury (Telen, 2020).
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH): By clearing toxic dicarbonyls, pyridoxamine reduces hepatic fat accumulation, steatosis, and collagen deposition while curbing liver tissue inflammation.

Scholarly Debates and Knowledge Gaps

The Clinical Translation Divergence

The primary academic debate surrounding pyridoxamine centers on the discrepancy between its clear, highly successful preclinical efficacy and its mixed performance in human clinical trials. While preclinical data overwhelmingly demonstrate broad tissue protection, clinical data (such as the Lewis et al. trial) reveal that its clinical efficacy diminishes once advanced tissue damage and macroscopic extracellular matrix cross-linking are fully established.

Key Knowledge Gaps & Required Data

  1. Definition of the Therapeutic Window: It remains unverified exactly when the transition occurs from reversible carbonyl stress to irreversible structural matrix cross-linking. Further clinical data utilizing non-invasive AGE biomarkers are required to identify the precise early-stage window where pyridoxamine provides maximum renoprotective and cardioprotective utility.
  2. Absence of Completed Phase 3 Data: Because the Phase 3 PIONEER registration trial was terminated due to corporate bankruptcy rather than safety concerns or clear clinical failure, there is an absolute deficit of large-scale Phase 3 human data validating long-term clinical endpoints (such as time-to-dialysis or hard cardiovascular events).
  3. High-Dose Neurological Safety Profiles: While short-term trials show an excellent safety profile, the long-term human safety of chronic, high-dose pyridoxamine requires deeper investigation. High doses of the structural vitamer pyridoxine are strongly associated with sensory neuropathy due to enzyme saturation and paradoxical inhibition of pyridoxal kinase; whether chronic, high-dose pyridoxamine carries a matching risk of peripheral nerve toxicity remains an unresolved question in longevity pharmacology.

References

Albersen, M., Bosma, M., Knoers, N. V. V. A. M., de Ruiter, B. H. B., Diekman, E. F., de Ruijter, J., Visser, W. F., de Koning, T. J., & Verhoeven-Duif, N. M. (2013). The intestine plays a substantial role in human vitamin B6 metabolism: A Caco-2 cell model. PLoS ONE, 8(1), e54113. https://doi.org/10.1371/journal.pone.0054113
Cited by: 59

Chetyrkin, S. V., Zhang, W., Hudson, B. G., Serianni, A. S., & Gaucher, S. P. (2007). Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: Mechanism of action of pyridoxamine. Biochemistry, 47(3), 997–1006. https://doi.org/10.1021/bi701190s
Cited by: 72

Haesen, S., Jager, M. M., Brillouet, A., de Laat, I., Vastmans, L., Verghote, E., Delaet, A., D’Haese, S., Hamad, I., Kleinewietfeld, M., Mebis, J., Mullens, W., Lambrichts, I., Wolfs, E., Deluyker, D., & Bito, V. (2024). Pyridoxamine limits cardiac dysfunction in a rat model of doxorubicin-induced cardiotoxicity. Antioxidants, 13(1), 112. https://doi.org/10.3390/antiox13010112
Cited by: 18

Lewis, E. J., Greene, T., Spitalewiz, S., Blumenthal, S., Berl, T., Hunsicker, L. G., Pohl, M. A., Rohde, R. D., Raz, I., Yerushalmy, Y., Yagil, Y., Herskovits, T., Atkins, R. C., Reutens, A. T., Packham, D. K., & Lewis, J. B. (2012). Pyridorin in type 2 diabetic nephropathy. Journal of the American Society of Nephrology, 23(1), 131–136. https://doi.org/10.1681/asn.2011030272
Cited by: 179

Reeve, E. H., Kronquist, E. K., Wolf, R. J., Lee, B., Khurana, A., Pham, H., Cullen, A. E., Peterson, J. A., Meza, A., Colton Bramwell, R., Villasana, L., Machin, D. R., Henson, G. D., & Walker, A. E. (2022). Pyridoxamine treatment ameliorates large artery stiffening and cerebral artery endothelial dysfunction in old mice. Journal of Cerebral Blood Flow & Metabolism, 43(2), 281–295. https://doi.org/10.1177/0271678x221130124
Cited by: 18

Skrypnyk, N. I., Voziyan, P., Yang, H., de Caestecker, C. R., Theberge, M. C., Drouin, M., Hudson, B., Harris, R. C., & de Caestecker, M. P. (2016). Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury. American Journal of Physiology-Renal Physiology, 311(2), F268–F277. https://doi.org/10.1152/ajprenal.00056.2016
Cited by: 38

Telen, M. J. (2020). Pyridoxamine: another vitamin for sickle cell disease? Haematologica, 105(10), 2348–2350. https://doi.org/10.3324/haematol.2020.257998
Cited by: 3

1 Like
#2

Paper: Quantification of the B6 vitamers in human plasma and urine in a study with pyridoxamine as an oral supplement; pyridoxamine as an alternative for pyridoxine (Clinical Nutrition, 2021)

The Safer B6: Why Pyridoxamine Could Safely Block the Formation of Advanced Glycation End-products (AGEs).

A small human pharmacokinetic study shows that oral pyridoxamine (PM) — a minor, non-toxic form of vitamin B6 — efficiently raises blood levels of the biologically active form (PLP) while generating almost none of the pyridoxine (PN) implicated in nerve-damaging B6 toxicity. It is the first published account of how PM is actually metabolised in humans.

Vitamin B6 has a dark side. The form found in nearly every supplement on the shelf — pyridoxine (PN) — is the same form repeatedly linked to sensory neuropathy when taken in excess. People reach for B6 expecting benefit and occasionally end up with tingling, numb, or painful limbs. The paradox is sharp: too much of the most common B6 supplement can mimic the very deficiency it was meant to fix, because high pyridoxine competitively interferes with the active cofactor.

Researchers at Maastricht University Medical Center asked a deceptively simple question: is there a better way to deliver vitamin B6? Their candidate is pyridoxamine (PM), a less famous member of the B6 family that does something the others do not — it scavenges reactive carbonyl compounds like methylglyoxal and blocks the formation of advanced glycation end-products (AGEs), the molecular “caramelisation” damage tied to diabetes and ageing.

The catch was that no one had ever properly tracked what happens to PM once swallowed by a human. So the team built a precise mass-spectrometry method and fed five healthy volunteers either a single 200 mg dose or three smaller 67 mg doses spread across a day.

The results were clean. PM was absorbed fast, peaked within about three hours, and then converted smoothly into the active cofactor PLP, which climbed roughly eight-fold and held a steady plateau. Crucially, the conversion to the troublesome pyridoxine stayed almost invisible — peak PN levels stayed below 15 nmol/L, thousands of times beneath the concentration a toxic pyridoxine dose would produce.

The split-dose regimen produced a flatter, more sustained PM level through the day, which may matter for any therapeutic use where constant exposure beats a single spike.

The big idea is a reframing: if you want the benefits of vitamin B6 — restoring the active cofactor, fighting glycation — without the neurotoxic baggage of pyridoxine, pyridoxamine may be the smarter molecule. It remains early-stage, five-person, healthy-volunteer data. But it provides the metabolic groundwork for treating B6 deficiency and metabolic disease with a form of the vitamin that, on this evidence, does not appear to poison the people taking it.

Actionable Insights

The take-home is mechanistic, not yet a dosing prescription, but the magnitudes are striking:

  • PLP restoration: A single 200 mg PM dose raised the active cofactor PLP from roughly 346 to 2787 nmol/L — about an 8-fold increase (+706%). Split dosing pushed PLP to ~3282 nmol/L and, unlike the single dose, kept accumulating over 24 hours rather than plateauing.
  • Active-form delivery without the toxic form: PM converted to PLP and PL (pyridoxal rose ~128-fold) while pyridoxine stayed below 15 nmol/L. The authors estimate a genuinely toxic 25 mg PN intake would yield ~30,000 nmol/L — meaning PM produced PN levels on the order of 2000-fold lower than the toxicity-relevant benchmark.
  • Practical framing: For anyone supplementing B6 for glycation/metabolic reasons, this suggests pyridoxamine as a candidate to achieve active-cofactor sufficiency while sidestepping the neuropathy risk that attaches to high-dose pyridoxine. The split-dose approach gives steadier daytime exposure.

Source:

Study Design Specifications

  • Type: Human clinical pharmacokinetic substudy (open-label, non-randomized crossover-style design within NCT02954588). Not a randomized controlled efficacy trial.
  • Subjects: Healthy human volunteers. N = 5 (3 male, 2 female; mean age 32 ± 9 y; mean BMI 21.9 ± 1.8). No diseased or control cohort in the disease sense — the “control” was a 2-participant dietary-only arm (no PM) to rule out background dietary B6.
  • Protocols: (1) Single 200 mg PM; (2) three daily 67 mg PM doses every 6 h; (3) diet-only control (n=2).
  • Analytical method: UPLC-MS/MS with deuterated internal standards; intra/inter-assay CV largely <5% for PM; LOQ in plasma 11.2 nmol/L (PM) to 121.4 nmol/L (PLP).

Bottom line: Solid, clean, first-in-human pharmacokinetics that make a credible mechanistic case for pyridoxamine as a lower-toxicity B6 form. It is not evidence of efficacy, longevity benefit, or chronic safety. Treat it as foundational PK groundwork — the “plumbing works” — that justifies, but does not substitute for, properly powered outcome trials.

#3

Paper: Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double-blind placebo-controlled trial (May, 2023)

Pyridoxamine and the Aging Brain’s Blood Supply: A Vitamin B6 Variant Keeps Mouse Arteries Young

In naturally aged mice, 7.5 months of the vitamin-B6 derivative pyridoxamine lowered blood pressure, softened stiffened large arteries, and rescued the function of the brain’s blood vessels — but only modestly protected memory, and notably without reducing the glycation end-products it was assumed to target.

One of the more durable ideas in vascular aging is that the body’s big arteries — the aorta and carotids — stiffen with age, and that this stiffness transmits damaging pulsatile pressure downstream into the delicate vessels of the brain. The hypothesis is attractive but has been hard to test cleanly, because most animal experiments induce stiffness artificially (through genetic knockouts or surgical calcification) rather than preventing it. This study runs the experiment in the more useful direction: take old mice, pharmacologically keep their large arteries from stiffening, and ask whether the brain’s vessels benefit.

The tool was pyridoxamine, a naturally occurring form of vitamin B6 that is chemically distinct from the common supplemental form (pyridoxine). Researchers gave it in drinking water to old male mice for roughly seven and a half months, from 20 to 27.5 months of age, and compared them with untreated old mice and young mice.

The vascular results were clear. Untreated old mice saw their systolic blood pressure climb over the treatment window; treated mice held steady. Aortic pulse wave velocity — the gold-standard stiffness readout — actually fell in treated animals while staying flat in controls. Most striking, the middle cerebral artery’s ability to dilate in response to a chemical signal was badly blunted in old controls but essentially restored to youthful levels in treated mice. Pharmacology experiments pinned this rescue on preserved nitric oxide, the key endothelial signaling molecule.

There were two important wrinkles. First, the benefit was vessel-specific: mesenteric (gut) arteries showed no improvement, suggesting the cerebral circulation is selectively responsive. Second, and more awkward for the textbook story, pyridoxamine did not reduce advanced glycation end-products (AGEs) in the aorta — the mechanism it is famous for. The authors instead lean on its antioxidant properties, supported by elevated expression of antioxidant genes (Sod1, Sod3) in the memory-critical hippocampus.

Cognition was the soft spot. Old mice were impaired on water-maze spatial memory and nest building; treated mice landed in an ambiguous middle ground — statistically indistinguishable from both young and old controls — which is what a weak or partial effect looks like with tiny groups. The authors reasonably suspect treatment started too late, after irreversible decline. The big idea survives: keep large arteries young, and the brain’s blood supply stays healthier. Whether that translates to preserved cognition, in females, or in humans, remains open.

Actionable Insights

The honest take-home is mechanistic, not prescriptive . This is a mouse study with no human efficacy data for vascular or cognitive endpoints.

That said, the effect sizes worth noting:

  • Blood pressure trajectory: Untreated old mice gained roughly +19 mmHg systolic over the window (113 → 132 mmHg); treated mice gained ~+9 mmHg (112 → 121, non-significant). The prevented rise is on the order of 10 mmHg — clinically meaningful if it held in humans.
  • Diastolic BP, treated vs untreated old: 90 vs 100 mmHg, a between-group Cohen’s d of approximately 0.72 (medium-large).
  • Cerebral artery dilation: Maximal acetylcholine-induced dilation went from ~30% (old control) to ~50% (treated) — a restoration of roughly two-thirds of the lost endothelial function, back to near-young levels. This is the headline benefit.

Critically, this is pyridoxamine specifically , not the pyridoxine in standard B6 supplements — the human cardiovascular B6 trials used pyridoxine and may have missed this. Pyridoxamine has a prior human safety record in diabetic nephropathy trials (24–52 weeks, no serious adverse events), but it has never been tested for arterial stiffness or brain vascular function in people.

Source:

Novelty — What This Adds

  • First demonstration that pharmacologically reducing large artery stiffness in naturally aged mice preserves cerebral artery endothelial function — the converse of prior transgenic (Eln+/−) and surgical (carotid calcification) models that increased stiffness. This closes the causal loop from the beneficial direction. [Confidence: High]
  • Establishes tissue specificity (cerebral yes, mesenteric no), which was not previously characterized for this intervention.
  • Provides a mechanistic correction: in this naturally aged model, the benefit is not AGE-mediated, challenging the standard rationale for pyridoxamine. [Confidence: Medium]

Critical Limitations (ruthless)

  1. Male-only. A hard generalizability ceiling. Sex differences in arterial stiffness and cerebrovascular aging are well documented and the authors flag this. No female data whatsoever.
  2. No lifespan or healthspan survival data. Despite “vascular aging” framing, this says nothing about whether pyridoxamine extends life or delays death.
  3. Uncontrolled dosing. Drug delivered in communal drinking water; treated mice drank less (5.9 vs 7.0 ml/day, p < 0.001), so actual per-animal dose is unknown and likely variable. Effect-dose relationships cannot be established.
  4. Underpowered cognition. Morris water maze and nest building ran at n = 4–5. The “partial preservation” claim rests on treated mice being statistically indistinguishable from both young and old controls — the classic signature of insufficient power, not a demonstrated intermediate effect. The post-hoc reanalysis of the 10–50 second probe window is a flexible analytic choice that inflates false-positive risk.
#4

Vitamin B6’s Promising Cousin Fails the Kidney Test — But Leaves a Door Ajar

A vitamin-B6–derived drug designed to block the sugar-driven protein damage that scars diabetic kidneys did not slow kidney decline overall in a year-long trial — but a pre-specified subgroup with the least existing damage showed a hint of benefit.

For decades, researchers have chased the idea that the slow destruction of diabetic kidneys is driven, in part, by “advanced glycation end products” (AGEs) — sticky, sugar-modified proteins that accumulate when blood glucose runs high for years. Pyridorin (pyridoxamine dihydrochloride), a metabolic relative of vitamin B6, was engineered to intercept exactly this chemistry: it blocks AGE formation, scavenges reactive oxygen species, and mops up toxic carbonyl intermediates. On paper, and in rats and mice, it looked like a near-ideal candidate to protect the kidney.

This trial put that promise to a rigorous test. Researchers from the Collaborative Study Group, led out of Rush University Medical Center, randomized 317 patients with advanced, proteinuric type 2 diabetic kidney disease to placebo or one of two Pyridorin doses (150 mg or 300 mg twice daily) for 52 weeks. All patients were already on maximal renin–angiotensin blockade — the existing standard of care — so the question was whether Pyridorin could add anything on top.

The headline result was negative. The primary endpoint — change in serum creatinine (a marker of kidney function, where a rise signals decline) over one year — showed no significant difference between either Pyridorin dose and placebo. Estimated GFR, cystatin C, and protein leakage into the urine were all likewise unmoved. By the strict standard the trial set itself, Pyridorin failed.

But the story has a twist the authors were honest about. They had pre-specified that patients with more intact kidneys might respond better, based on prior work with a similar drug. When they split patients into thirds by baseline kidney function, the group with the healthiest kidneys (lowest creatinine) showed a statistically significant slowing of decline on Pyridorin. A continuous-variable analysis of this interaction was strongly significant. The interpretation: by the time a diabetic kidney is heavily scarred — and many of these patients already had advanced fibrosis — interrupting an earlydamage pathway may simply be too late to matter.

The authors are appropriately circumspect. Subgroup findings from underpowered slices of a negative trial are notoriously unreliable, and they say so plainly. The honest conclusion is not “Pyridorin works,” but “Pyridorin did not work here, and the only signal of life is a hypothesis-generating one that demands a properly powered trial in earlier-stage patients.” That trial, to date, has not delivered a licensed drug — a sober reminder that mechanistic elegance in a test tube does not guarantee clinical benefit. [Confidence: High]

Actionable Insights

For a longevity/biohacker audience the take-home is mostly cautionary, and the effect sizes make the case.

There is no actionable personal-supplementation insight here. Pyridoxamine is sometimes sold as a B6 supplement, but this trial gives no support for self-dosing it to protect kidneys. The overall primary endpoint effect size was effectively zero: placebo creatinine rose 0.36 mg/dl, the 300 mg arm rose 0.36 mg/dl (Cohen’s d ≈ 0.0), and the 150 mg arm actually did marginally worse (0.42 mg/dl).

The only positive signal was small and confined to early disease. In the lowest-creatinine tertile, one-year creatinine rise was 0.28 (placebo) vs 0.07 (150 mg) and 0.14 (300 mg) mg/dl — a calculated Cohen’s d of roughly 0.30–0.45 (small-to-moderate). The corresponding eGFR preservation was 3.8 ml/min/1.73m² for 150 mg (P=0.03), but only 1.45 for 300 mg (P=0.39) — an incoherent dose-response that undercuts confidence.

Practical message: disease-stage timing dominates. Anti-AGE strategies, if they work at all, likely require intervention before substantial fibrosis sets in — a general longevity principle (treat early) more than a Pyridorin endorsement.

Source:

  • Open Access Paper: Pyridorin in Type 2 Diabetic Nephropathy
  • Lead Institution: Rush University Medical Center / The Collaborative Study Group, Chicago, Illinois.
  • Country: United States (multicenter, with sites in Israel and Australia).
  • Journal: Journal of the American Society of Nephrology (JASN).
  • Funding/COI: Funded by NephroGenex Inc. (the drug’s sponsor); three authors, including both lead Lewises and the trial statistician, drew salary from NephroGenex research grants. This is a material conflict to weigh against the favorable subgroup framing.
  • Impact Evaluation: JASN’s 2024 Journal Impact Factor is 9.4 (Clarivate Journal Citation Reports, via the publisher’s platform), with a Scopus CiteScore of 16.8, therefore this is a High impact journal

Study Design Specifications

  • Type: Clinical Trial — Phase 2, double-blind, randomized, placebo-controlled, three-arm (1:1:1), 52 weeks.
  • Subjects (human): 317 randomized adults (≥25 yr) with type 2 diabetes and proteinuric nephropathy on maximal ACEi/ARB.
    • Placebo n=106 (103 analyzed), PYR 150 mg BID n=105 (99 analyzed), PYR 300 mg BID n=106 (105 analyzed).
    • Baseline: age 63.9±9.5 yr; diabetes duration 17.6±8.5 yr; serum creatinine 2.20±0.57 mg/dl; UPCR 2973±1932 mg/g; ~74% male, ~81% white. Groups well-balanced.

Organ-specific priority: the glomerulus. The authors’ own framing is mechanistically the most important finding: an early-pathway interruptor cannot reverse established fibrosis. Prior morphology data cited in-paper indicate patients near 2 mg/dl creatinine typically already have ≥50% global glomerulosclerosis and advanced interstitial fibrosis. This is the textbook “point of no return” problem — consistent with the broader geroscience principle that interventions targeting initiating events lose traction once downstream structural damage accumulates.

#5

The B6 Your Multivitamin Forgot: A Vitamin Cousin Keeps Aging Arteries Supple and Brain Blood Flow Flowing

In old mice, 7.5 months of pyridoxamine — an uncommon form of vitamin B6 — halted the age-related rise in blood pressure, softened stiffened large arteries, and rescued endothelial function in brain arteries. Cognitive benefits were real but modest, and the proposed anti-glycation mechanism failed to show up.

Arteries stiffen with age. This is not cosmetic plumbing trivia — a rigid aorta transmits punishing pressure pulses downstream into the delicate small vessels of the brain, where it damages the endothelial lining, throttles blood flow, and is repeatedly linked in humans to cognitive decline and dementia. The open question has always been directional: if you could keep the big arteries supple in an already-old animal, would the brain’s vessels and the mind they feed actually benefit? Or is the damage, by old age, already locked in?

A team led by Ashley Walker at the University of Oregon went after that question with pyridoxamine, a specific form of vitamin B6 that is not the pyridoxine in your supplement aisle. Old male mice (starting at 20 months, roughly a 55-year-old human, and continuing to ~27.5 months) drank pyridoxamine-laced water for over seven months. The results were cleaner on the vascular side than the cognitive side.

Mechanically, pyridoxamine worked. Control mice saw systolic blood pressure climb roughly 19 mmHg over the study; treated mice held essentially flat. Aortic pulse wave velocity — the gold-standard stiffness readout — dropped in treated animals from before to after, while controls didn’t budge. Carotid arteries were measurably less stiff. Most striking, the brain’s middle cerebral arteries in treated mice dilated like those of young mice, and the team traced this to preserved nitric oxide signaling, the endothelium’s core vasodilator currency. Notably, this rescue was brain-specific: mesenteric (gut) arteries got no such benefit, hinting the cerebral circulation is uniquely responsive.

Then the story gets more honest. Cognition, measured by water-maze memory and instinctive nest-building, was only partially preserved — statistically borderline, with small groups and a clear sense that starting treatment at 20 months may simply be too late. And the textbook explanation for how pyridoxamine helps — by blocking advanced glycation end-products (AGEs), the sugar-protein crosslinks that stiffen tissue — collapsed: the team found no AGE differences at all, partly because their old mice didn’t even show the expected age-related AGE buildup. The authors pivot to pyridoxamine’s antioxidant activity as the likelier driver, supported by raised antioxidant gene expression (Sod1, Sod3) in the hippocampus.

The big idea: vascular aging in the brain may be partly reversible from outside the brain, by treating the arteries upstream — but the window matters, and the mechanism is not what we assumed.

Actionable Insights

The honest take-home for humans is “interesting target, not yet an instruction.” This is a male-mouse study with no human arterial-stiffness or cognition data behind it.

That said, the effect sizes on the vascular outcomes are not trivial. The blood-pressure divergence is the most concrete: control mice gained roughly 19 mmHg systolic (a large within-group effect, approximate Cohen’s d ~1.1) while treated mice held flat — in human terms, the difference between drifting into stage-2 hypertension and not. The cerebral artery dilation difference between treated and untreated old mice was large (approximate d ~1.2, figure-derived), restoring young-like function.

The mechanistic insight is the more durable lesson: the benefit tracked antioxidant capacity, not glycation. So the generalizable message is that interventions preserving endothelial nitric oxide and antioxidant defense (the same axis hit by aerobic exercise, which is already evidence-backed in humans for arterial compliance) are the plausible lever — pyridoxamine is one candidate molecule on that axis, not a proven one. Crucially: timing. Benefits were blunted by starting in old age, suggesting earlier-is-better for any such strategy.

Source:

  • Open Access Paper: Pyridoxamine treatment ameliorates large artery stiffening and cerebral artery endothelial dysfunction in old mice
  • Institution: University of Oregon (lead), with University of Utah, Legacy Health (Portland), and Florida State University
  • Country: United States
  • Journal: Journal of Cerebral Blood Flow & Metabolism (SAGE; official journal of the International Society for Cerebral Blood Flow & Metabolism), 2023, Vol. 43(2): 281–295
  • Impact Evaluation: The impact score of this journal is 4.5, evaluated against a typical high-end range of 0–60+ for top general science journals, therefore this is a Medium impact journal. Within its own specialist field (cerebrovascular physiology and neurovascular imaging) it is a well-regarded, solidly mid-to-upper-tier outlet rather than a glamour generalist venue.

Novelty

What’s genuinely new: this is the first demonstration that pharmacologically reducing large-artery stiffness in already-old animals preserves cerebral artery endothelial function, and that the effect is NO-mediated and anatomically selective for the cerebral circulation over the mesenteric. Prior causal work relied on transgenic or surgical stiffness models; this shows a tractable intervention in normal aging. The negative AGE finding is also informative — it weakens the long-assumed anti-glycation rationale and reorients attention toward antioxidant mechanisms.

Critical Limitations

  • Males only. The authors concede this. Given documented sex differences in arterial stiffness and that women carry disproportionate late-life cerebrovascular/dementia risk, generalizability is unestablished. This alone caps translational confidence.
  • Cognitive data are thin. N≈4–5 per group for the headline behavioral tests. The water-maze “benefit” required a post hoc re-slicing of the probe trial to the 10–50 second window; the full 60-second probe showed no group passing. Nest-building “preservation” was not statistically distinct from either young or old control — i.e., the treated group is genuinely intermediate/ambiguous, not clearly rescued. Calling cognition “partially preserved” is charitable; “inconclusive, trending positive” is more accurate.
  • Mechanism unresolved. The pre-registered hypothesis (anti-AGE) failed. The fallback (antioxidant) is plausible but inferred from gene expression, not protein/activity or causal blockade. They cannot separate whether cerebral benefit comes from upstream destiffening, lower blood pressure, or direct cerebral action.
  • Confounded BP/stiffness causality. SBP and PWV moved together; the design cannot say which drives which.
  • Dosing uncontrolled. Drug was in communal water; per-animal intake unknown, and treated mice drank less. Effective dose is uncertain.
#6

How does it compare to SGLT-2 inhibitors?

#7

On what variable do you want to compare SLGT2 inhibitors and pyridoxamine - only AGE, or something else?

#8

The FDA involvement here makes me furious. Will no one get ahold of the brain worm eaten RFK to add pyridoxamine to the list of substances they’re deregulating?

1 Like
#9

Agreed, but its not just the USA:

There is currently no major global jurisdiction where pyridoxamine (PM) is legally authorized to be sold over the counter (OTC) to consumers as a dietary supplement or general-sale health product.

While biochemically classified as a natural vitamer of Vitamin B6, pyridoxamine is uniformly restricted across primary international regulatory frameworks. This restriction stems from two distinct regulatory mechanisms: pharmaceutical preclusion clauses and exclusive positive-list systems for nutritional ingredients.

#10

Vascular Aging and Arterial Stiffness, Reno protection, (MASH), Cardiomyopathy

#11

Comparison on the Primary Molecular and Pharmacological Mechanisms

Pyridoxamine

Pyridoxamine is a natural vitamer of vitamin B6 that acts as an inhibitor of Advanced Glycation End-products (AGEs) and Advanced Lipoxidation End-products (ALEs). Its molecular action occurs through three distinct pathways:

  • Metal Chelation: It sequesters catalytic redox-active metal ions required for carbohydrate and lipid oxidation.
  • Carbonyl Trapping: It directly traps reactive carbonyl species (RCS) intermediates—such as methylglyoxal, glyoxal, and 3-deoxyglucosone—preventing their propagation into permanent macromolecular cross-links.
  • Post-Amadori Inhibition: It interacts with post-Amadori intermediates to block the subsequent polymerization and cross-linking of long-lived structural proteins like collagen and elastin.

SGLT2 Inhibitors

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin, canagliflozin) target the high-capacity sodium-glucose cotransporter 2 in the S1 segment of the renal proximal convoluted tubule. By blocking the reabsorption of roughly 90% of filtered glucose, they trigger systemic pleiotropic transformations:

  • Fasting-Mimetic Induction: Induced glucose excretion creates a persistent calorie deficit, activating systemic energy sensors such as AMP-activated protein kinase (AMPK) and Sirtuin 1 (SIRT1), while downregulating mechanistic target of rapamycin (mTOR).
  • Metabolic Substrate Shifting: They shift systemic metabolism toward hepatic ketogenesis, elevating circulating levels of beta-hydroxybutyrate, which serves as an energetically efficient fuel for myocardial and renal tissues.
  • Hemodynamic Unloading: They induce natriuresis and osmotic diuresis, selectively depleting interstitial fluid volume to lower cardiac preload and afterload.
  • Inflammasome Suppression: They inhibit the NLRP3 inflammasome, reducing chronic low-grade systemic inflammation.

Phenotypic Comparative Analysis

1. Vascular Aging and Arterial Stiffness

  • Pyridoxamine: Directly addresses structural vascular remodeling. In preclinical models of aging and diabetes, it prevents the cross-linking of aortic collagen fibers. This structural modification preserves large-artery compliance, reduces total peripheral resistance, increases wave transit time, and diminishes myocardial afterload. However, it does not dynamically modulate acute endothelial vasoactivity. PubMed Reference (21316441).
  • SGLT2 Inhibitors: Alleviate both functional and structural arterial stiffness. Clinical trials show consistent reductions in central systolic blood pressure and pulse wave velocity (PWV). Rather than cleaving established AGE cross-links, SGLT2 inhibitors attenuate endothelial cell activation, enhance endothelial nitric oxide synthase (eNOS) activation to improve vasodilation, and reduce vascular smooth muscle cell oxidative stress. PubMed Reference (35426600).

2. Renoprotection

  • Pyridoxamine: Evaluated clinically under the investigational name Pyridorin to arrest diabetic nephropathy. A major Phase III randomized controlled trial in advanced, proteinuric Type 2 diabetic nephropathy failed to meet its primary endpoint of reducing serum creatinine changes over 52 weeks across the full intent-to-treat population. Post-hoc subgroup analyses suggested eGFR preservation was restricted solely to cohorts with early-stage, less advanced renal impairment. PMC Reference (3269925).
  • SGLT2 Inhibitors: Possess robust, landmark-validated clinical efficacy (CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials) and are established as standard-of-care. The primary mechanism is hemodynamic restoration of tubuloglomerular feedback. Increased solute delivery to the macula densa induces afferent arteriolar vasoconstriction, lowering intraglomerular hydrostatic pressure and mitigating hyperfiltration-mediated sclerosis. Secondary mechanisms include reduced renal interstitial inflammation and down-regulated Transforming Growth Factor-beta (TGF-beta) expression.

3. Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • Pyridoxamine: Evidence is restricted to early preclinical rodent models. While it mitigates hepatic AGE/ALE accumulation and reduces crude markers of lipid peroxidation, there is currently no human clinical or biopsy-validated data demonstrating the resolution of steatosis, lobular inflammation, or fibrosis.
  • SGLT2 Inhibitors: Exhibit definitive, histologically verified efficacy. The induced glucose clearance promotes hepatic fatty acid beta-oxidation and downregulates de novo lipogenesis. Elevated beta-hydroxybutyrate suppresses pathogenic CD8+ T-cell effector functions and inhibits hepatic NLRP3 inflammasome activation. The multicenter DEAN randomized controlled trial confirmed a 53% success rate in histological MASH improvement (>= 2-point reduction in NAFLD Activity Score without worsening fibrosis). PMC Reference (12966765).

4. Cardiomyopathy

  • Pyridoxamine: Preclinical data shows mitigation of myocardial stiffening by preventing the glycation of titin and extracellular collagen, which normalizes left ventricular end-diastolic pressure (LVEDP) and diastolic filling kinetics in rodents. These structural findings have not successfully translated into human heart failure endpoint clinical trials.
  • SGLT2 Inhibitors: Represent a guideline-directed foundational class for heart failure across reduced, mildly reduced, and preserved ejection fractions (DAPA-HF, EMPEROR, and DELIVER trials). Cardioprotection is driven by optimized myocardial energetics (utilizing ketones over glucose), direct inhibition of myocardial sodium-hydrogen exchanger 1 (NHE1) to reduce intracellular sodium/calcium overload, preload/afterload reduction, and suppression of pro-fibrotic adipokines (IL-6, TNF-alpha) secreted from epicardial adipose tissue.

Synthesis Matrix

Feature / Outcome Pyridoxamine SGLT2 Inhibitors
Primary Molecular Target Reactive carbonyl intermediates; post-Amadori complexes. SGLT2 transporter in the S1 renal proximal tubule.
Vascular Aging Mechanism Inhibits/prevents structural AGE cross-linking of collagen/elastin. Enhances eNOS; lowers VSMC tone; dampens endothelial activation.
Renoprotective Status Failed Phase III primary endpoints; benefit restricted to early-stage CKD. Class-I guideline recommendation; definitive eGFR preservation.
MASH Status Preclinical animal models only; no human histological data. Biopsy-proven efficacy (DEAN trial); significantly reduces NAS score.
Cardiomyopathy Status Normalizes structural extracellular stiffness (titin/collagen) in rodents. Class-I guideline recommendation for Heart Failure; optimizes energetics.
Clinical Translation Highly limited; halted or stalled development for major chronic indications. Universal; robustly validated across large-scale global clinical trials.

Scholarly Debates, Knowledge Gaps, and Data Requirements

The “Late-Stage Intervention” Debate in Glycation Kinetics

A major scholarly debate surrounding pyridoxamine is whether any purely anti-AGE therapy can succeed clinically if initiated after macrovascular and microvascular structural damage is established. Because covalent AGE cross-links in mature extracellular matrix collagen possess a long half-life measured in years to decades, pyridoxamine’s mechanism is inherently prophylactic or restricted to early-stage disease. It cannot rapidly reverse existing macrostructural cross-links. To definitively test if pyridoxamine possesses true longevity-extending or geroprotective value in humans, clinical trials require enrollment of middle-aged cohorts prior to the onset of clinical organ dysfunction, utilizing non-invasive, long-term markers of ECM aging such as skin autofluorescence or mass-spectrometry analysis of skin biopsies.

SGLT2 Inhibitor Receptor Asymmetries

While the systemic benefits of SGLT2 inhibitors are clear, a knowledge gap exists regarding the precise intermediary signaling cascades driving their extra-renal benefits. SGLT2 receptors are not significantly expressed in healthy myocardial tissue, vascular endothelial cells, or hepatocytes. Therefore, the profound benefits observed in cardiomyopathy, arterial stiffness, and MASH are mediated through systemic metabolic shifts (such as the “thrifty substrate” hypothesis of beta-hydroxybutyrate utilization) or off-target interactions with related transporters (like NHE1). Resolving this debate requires tissue-specific knockout animal models and radiolabeled tracer kinetic studies in humans to map exactly how proximal tubule inhibition translates into distal organ protection.

1 Like
#12

I remember when it was banned from supplements. This really pisses me off that the pharmaceutical company ruined it for everyone and then went bankrupt from incompetence so now we can’t get it as a drug OR a supplement. :rage:

#13

Thanks, this confirms to me that this compound doesn’t move the needle much if I’m already on a SGLT-2 inhibitor

#14

Some would view France as a major global jurisdiction
Seems it’s available there as a supplement on Supersmart.com.
pyridoxamine HCl 100mg, 60 caps, 28.5Euros.
Malheureusement, they do not ship outside of France.
So… next time you’re there…

1 Like
#15

I wrote an article about pyridoxamine for longevity in 2009 just before it became largely forgotten because it got banned by the FDA as a supplement. In case of interest here is the link to it:

The main things in the article still stand, even though the research is somewhat outdated. I think it’s an undervalued supplement and would like to see a lifespan study on it.

Keep in mind that even though SGLT-2 inhibitors may be more effective overall, pyridoxamine has a completely different mechanism of action and should give benefits that are additive to SGLT-2 use. This is because SGLT-2 doesn’t directly reduce any of the glycation reactions that pyridoxamine inhibits. It mainly reduces the amount of substrate (glucose) that can glycate molecules, but doesn’t directly attack the glycation per se.

2 Likes
#16

But I don’t think thats the version you really want…

From Claude 4.8 Opus:

What, if anything, differs between pyridoxine HCl, Pyridoxamine, and Pyridoxamine Dihydrochloride? Is there likely a difference in terms of efficacy, in human health applications?

Three things are being compared here, and they fall into two different categories of difference: a genuine molecular difference (pyridoxine vs pyridoxamine) and a trivial salt-form difference (pyridoxamine vs pyridoxamine dihydrochloride). They’re easy to conflate but matter very differently.

The chemistry

All three are built on the same pyridine ring shared by every vitamin B6 vitamer (2-methyl, 3-hydroxy, 5-hydroxymethyl). The only structural variable that matters is the substituent at the 4’ position:

Form 4’ group What it is
Pyridoxine (as HCl) –CH₂OH (hydroxymethyl) The standard supplemental/fortification vitamer, sold as the hydrochloride salt
Pyridoxamine –CH₂NH₂ (aminomethyl) The free base
Pyridoxamine dihydrochloride –CH₂NH₂ (aminomethyl) The same molecule as pyridoxamine, as a 2×HCl salt

So pyridoxine and pyridoxamine are chemically distinct molecules — hydroxymethyl vs aminomethyl at 4’. Pyridoxamine and pyridoxamine dihydrochloride are the same molecule, differing only in counterion.

Pyridoxamine vs pyridoxamine dihydrochloride — essentially no biological difference. The dihydrochloride exists because pyridoxamine has two protonatable nitrogens (the ring nitrogen and the 4’-primary amine), so it forms a di-salt. Practically, the salt is more stable, more water-soluble, and easier to formulate and dose accurately — which is why both the Pyridorin drug program and most supplements used it. Once dissolved and absorbed, it dissociates to the identical pyridoxamine cation. The only quantitative wrinkle is mass: pyridoxamine free base is ~168 g/mol and the dihydrochloride ~241 g/mol, so roughly 70% of a dihydrochloride dose is actual pyridoxamine (vs ~82% pyridoxamine in pyridoxine HCl). Label dosing should specify which basis is used, but pharmacodynamically they’re interchangeable.

Pyridoxine vs pyridoxamine — a real functional difference. That 4’-amino group is not cosmetic. It’s a nucleophilic primary amine that lets pyridoxamine do things pyridoxine cannot: trap reactive dicarbonyls (methylglyoxal, glyoxal) and post-Amadori intermediates, blocking advanced glycation and lipoxidation end-product (AGE/ALE) formation; chelate redox-active metals (Cu²⁺, Fe³⁺) that catalyze glycoxidation; and scavenge hydroxyl radicals via the ring’s 3-hydroxyl. Pyridoxine, lacking the amine, has essentially none of this anti-glycation/carbonyl-scavenging activity. This is exactly the distinction the Reeve paper rested on — and why it pointedly noted the large human cardiovascular B6 trials used pyridoxine and may have missed any pyridoxamine-specific benefit.

Efficacy in human applications

This splits into two very different questions.

As a vitamin (correcting B6 status / feeding the PLP pool): all three are interconvertible in vivo and ultimately supply pyridoxal-5’-phosphate, the active coenzyme. For preventing or treating deficiency, they’re broadly equivalent on a molar basis. The choice between them is irrelevant here.

As a “pharmaco-nutrient” exploiting the anti-glycation/antioxidant chemistry: only pyridoxamine qualifies, and here the honest verdict is that the elegant mechanism has not translated into demonstrated human efficacy. The largest completed trial — a phase 2 in 317 patients with type 2 diabetic nephropathy over 52 weeks — did not show a significant change in serum creatinine for either Pyridorin dose compared with placebo, missing its primary endpoint, with only post-hoc subgroup signals (e.g., less advanced disease). The phase 3 program was pursued on the basis of post-hoc phase 2 data suggesting a non-dose-dependent benefit of marginal statistical significance, and it was never completed — NephroGenex went bankrupt around 2016 and the IND was withdrawn in 2017. So for its lead indication, pyridoxamine has no confirmed disease-modifying efficacy from an adequately powered, completed trial. The vascular/cerebrovascular application from the Reeve paper is purely preclinical (aged male mice) with no human data at all. PubMedPubMed Central

Safety and access also differ, and this matters practically:

  • Pyridoxine carries the one well-established B6 toxicity: chronic high-dose intake causes sensory peripheral neuropathy, which is why the adult tolerable upper intake level (US) sits at 100 mg/day. This neuropathy is specifically tied to the pyridoxine form, which is a real consideration if someone is taking high-dose B6.
  • Pyridoxamine had an acceptable safety profile across 24–52 week human trials, but in the US it occupies an unusual regulatory limbo: FDA determined that pyridoxamine is excluded from the dietary supplement definition because it was authorized for investigation as a new drug (Pyridorin) with substantial public clinical investigation, and may not be marketed as a supplement. A 2017 citizen petition asked FDA to reverse this now that the drug program has ceased, but the 2009 exclusion is the governing position. It’s marketed as a supplement in some other countries. FDA Law BlogFDA Law Blog

Bottom line: If the goal is B6 repletion, the three are interchangeable and the salt form is a non-issue. If the goal is the anti-glycation/antioxidant pharmacology, pyridoxine is not a substitute for pyridoxamine — but pyridoxamine itself, despite a mechanistically compelling story and promising rodent and preclinical data, has yet to prove clinical efficacy in humans for any indication, and the pivotal trial that might have settled it was abandoned for financial rather than scientific reasons. [Confidence: High on the chemistry and regulatory facts; High that no completed phase 3 efficacy exists; Medium on the mechanistic relevance to vascular aging, which remains preclinical.]